DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Information source: National Cancer Institute (NCI)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Recurrent Melanoma; Stage IV Melanoma

Intervention: cyclophosphamide (Drug); fludarabine phosphate (Drug); therapeutic autologous lymphocytes (Biological); in vitro-treated peripheral blood stem cell transplantation (Procedure); gp100 antigen (Biological); MART-1 antigen (Biological); incomplete Freund's adjuvant (Biological); filgrastim (Biological); aldesleukin (Biological)

Phase: Phase 2

Status: Terminated

Sponsored by: National Cancer Institute (NCI)

Official(s) and/or principal investigator(s):
Steven Rosenberg, Principal Investigator, Affiliation: National Cancer Institute Surgery Branch

Summary

This randomized phase II trial is studying how well giving vaccine therapy with or without interleukin-2 after chemotherapy and an autologous white blood cell infusion works in treating patients with metastatic melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy with interleukin-2, chemotherapy, and an autologous white blood cell infusion may be a more effective treatment for metastatic melanoma.

Clinical Details

Official title: A Phase II Study Using a Peptide Vaccine With or Without Aldesleukin Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Objective clinical response (CR or PR)

Secondary outcome:

Presence of anti-tumor T cells

Recovery of regulatory T cells

Incidence of DLTs and SAEs graded according to CTCAE version 3.0

Detailed description: PRIMARY OBJECTIVES: I. Determine the ability of gp100 and MART-1 peptide vaccines with or without a high-dose interleukin-2 (IL-2), when administered after a nonmyeloablative, lymphodepleting preparative regimen and reinfusion of autologous CD25+ T-regulatory-depleted lymphocytes, to mediate tumor regression in patients with metastatic melanoma. SECONDARY OBJECTIVES: I. Determine the generation of antitumor lymphocytes and the rate of repopulation of CD25+ T-regulatory cells in patients treated with this regimen. II. Determine the toxicity of this treatment regimen. OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising

cyclophosphamide IV over 1 hour on days - 8 and -7 and fludarabine IV over 15-30 minutes on

days - 6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes

on day 0. Patients receive vaccination with gp100: 209-217 (210M) and MART-1: 27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover. ARM II: Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 1-3 months.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of metastatic melanoma

- No tumor reactive cells available for cell transfer therapy

- Measurable disease

- Previously treated with interleukin-2 (IL-2) and meets 1 of the following criteria:

- No response (progressive disease)

- Recurrent disease

- HLA*0201 positive

- ECOG performance status 0 or 1

- Absolute neutrophil count > 1,000/mm^3

- Platelet count > 100,000/mm^3

- Hemoglobin > 8. 0 g/dL

- ALT and AST < 3 times upper limit of normal

- Bilirubin ≤ 2. 0 mg/dL (< 3. 0 mg/dL if Gilbert's disease is present)

- Creatinine ≤ 2. 0 mg/dL

- Life expectancy ≥ 3 months

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for up to 4 months after

receiving the preparative regimen

- No active systemic infections, coagulation disorders, or other major medical

illnesses of the cardiovascular, respiratory, or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, or obstructive or restrictive pulmonary disease

- No autoimmune disease (e. g., autoimmune colitis or Crohn's disease) or primary

immunodeficiency disease

- No HIV positivity

- No hepatitis B or C virus positivity

- No Epstein-Barr virus negativity

- Eligible to receive high-dose IL-2, as evidenced by the following:

- Patients ≥ 50 years of age must have a normal cardiac stress test (e. g., stress

thallium, stress MUGA, dobutamine echocardiogram, or other stress test) AND LVEF ≥ 45%

- Patients with a history of EKG abnormalities, symptoms of cardiac ischemia, or

arrhythmias must have a normal cardiac stress test AND LVEF ≥ 45%

- Patients with a prolonged history of cigarette smoking or symptoms of

respiratory dysfunction must have a normal pulmonary function test, as evidenced by FEV 1 ≥ 60% of predicted

- At least 4 weeks since prior systemic therapy

- At least 6 weeks since prior nitrosourea therapy

- No concurrent systemic steroid therapy

- Recovered immune competence after prior chemotherapy or radiotherapy

- No prior gp100: 209-217 or MART-1: 27-35 peptide vaccine

Locations and Contacts

National Cancer Institute Surgery Branch, Bethesda, Maryland 20892-1201, United States
Additional Information

Starting date: November 2005
Last updated: June 5, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017